# ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

> **NCT00272987** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **DRUG:** paclitaxel
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00272987
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12-13
- **Primary completion:** 2009-07-31
- **Final completion:** 2019-10-21
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272987, "ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00272987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*